Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.540
-0.050 (-3.14%)
At close: Dec 5, 2025, 4:00 PM EST
1.610
+0.070 (4.55%)
After-hours: Dec 5, 2025, 7:34 PM EST

Akebia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
409415234106395405
Upgrade
Market Cap Growth
4.07%77.46%120.08%-73.16%-2.30%-46.16%
Upgrade
Enterprise Value
441484301121363241
Upgrade
Last Close Price
1.541.901.240.582.262.80
Upgrade
Forward PE
78.97-----
Upgrade
PS Ratio
1.682.591.200.361.871.37
Upgrade
PB Ratio
9.82-8.43-7.6420.305.341.63
Upgrade
P/TBV Ratio
-----8.36
Upgrade
P/FCF Ratio
12.70-----
Upgrade
P/OCF Ratio
12.61-----
Upgrade
EV/Sales Ratio
1.963.021.550.411.710.82
Upgrade
EV/EBITDA Ratio
13.68--39.44--
Upgrade
EV/FCF Ratio
13.71-----
Upgrade
Debt / Equity Ratio
4.79-3.84-4.7230.072.560.51
Upgrade
Debt / EBITDA Ratio
5.34--18.82--
Upgrade
Asset Turnover
0.790.690.650.660.360.42
Upgrade
Inventory Turnover
1.921.642.130.771.670.72
Upgrade
Quick Ratio
1.741.070.821.010.791.59
Upgrade
Current Ratio
1.941.411.181.431.041.99
Upgrade
Return on Equity (ROE)
----237.83%-175.37%-119.82%
Upgrade
Return on Assets (ROA)
4.80%-12.49%-9.30%-4.89%-24.27%-15.41%
Upgrade
Return on Capital (ROIC)
9.35%-22.81%-20.14%-10.17%-44.71%-24.88%
Upgrade
Return on Capital Employed (ROCE)
9.50%-33.10%-31.40%-15.30%-84.90%-38.20%
Upgrade
Earnings Yield
-3.89%-16.74%-22.23%-88.77%-71.32%-95.09%
Upgrade
FCF Yield
7.87%-9.82%-10.01%-69.03%-63.99%-27.35%
Upgrade
Buyback Yield / Dilution
-20.49%-12.53%-2.56%-10.14%-19.85%-16.95%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.